Treatment duration of Trastuzumab in early HER2-positive breast cancer

Languages

Service navigation

Search

Contact information

Treatment duration of Trastuzumab in early HER2-positive breast cancer

The drugs trastuzumab and pertuzumab are used in Switzerland to treat breast cancer if cancer cells overexpress the HER2 receptor. The approved treatment duration of trastuzumab is a maximum of 12 months and can be started before or after surgical removal of cancer cells. An HTA report was commissioned to evaluate the reimbursement requirement with the aim of reviewing the efficacy, safety, cost-effectiveness and budgetary impact. The HTA report examines the 12-months treatment duration compared with a shorter duration of 6 months for HER2-positive early breast cancer.

Dokumente

HTA protocol (PDF, 527 kB, 28.07.2023)

Stakeholder feedback on the HTA report (PDF, 238 kB, 28.07.2023)

Last modification 28.07.2023

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/trastazumab.html